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Background:Myosin VI turnover during endocytosis is underexplored.
Results:Wild type myosin VI exchanges at the same rate as its binding partner and faster than artificially dimerized myosin VI.
Conclusion:During endocytic exchange, myosin VI relies on binding partner dynamics and does not function as a stable dimer.
Significance: The turnover dynamics and monomer/dimer properties of myosin VI are illuminated.
The actin-based molecular motor myosin VI functions in the
endocytic uptake pathway, both during the early stages of clath-
rin-mediated uptake and in later transport to/from early endo-
somes. This study uses fluorescence recovery after photobleach-
ing (FRAP) to examine the turnover rate of myosin VI during
endocytosis. The results demonstrate that myosin VI turns over
dynamically on endocytic structures with a characteristic half-
life common to both the large insert isoform of myosin VI on
clathrin-coated structures and the no-insert isoform on early
endosomes. This half-life is shared by the myosin VI-binding
partner Dab2 and is identical for full-length myosin VI and the
cargo-binding tail region. The 4-fold slower half-life of an arti-
ficially dimerized construct of myosin VI on clathrin-coated
structures suggests that wild type myosin VI does not function
as a stable dimer, but either as a monomer or in a monomer/
dimer equilibrium. Taken together, these FRAP results offer
insight into both the basic turnover dynamics and the mono-
mer/dimer nature of myosin VI.
The myosins in class VI are distinguished in their role as
intracellular motor proteins by their unique ability to move
toward the minus end of actin filaments (1). This directional
bias, determined by the presence of a 53-amino acid insert
(reverse gear) proximal to the motor domain (2), renders myo-
sin VI a critical functional component of several, direction-
specific intracellular processes. For example, in the secretory
pathway, myosin VI maintains Golgi complex morphology (3)
and is required for the sorting of cargo to the leading edge of
motile cells (4) and to the basolateral domain of polarized epi-
thelial cells (5). In this pathway, myosin VI has also been shown
to modulate the fusion of secretory vesicles with the plasma
membrane during the final stages of exocytosis (6).
Myosin VI has also been broadly implicated in endocytosis,
the critical cellular pathway by which essential proteins and
nutrients are transferred from the external environment to the
interior of a cell. The mammalian myosin VI isoform with a
21–31-amino acid “large insert” (LI)3 just before theC-terminal
cargo-binding portion of the tail domain (7) is specifically
linked with the early stages of the clathrin-mediated endocytic
pathway, a subcategory of endocytosis involving uptake into
pits and vesicles coated with the protein clathrin (“clathrin-
coated structures”). This myosin VI LI splice variant is selec-
tively expressed in polarized epithelial cells, where it co-local-
izes at the apical domainwith clathrin-coated structures (7) and
has been shown by total internal reflection fluorescence
microscopy to be actively recruited to clathrin-coated struc-
tures (8). Studies from the myosin VI KO mouse, the Snell’s
waltzer mouse, have demonstrated that myosin VI is essential
for cystic fibrosis transmembrane conductance regulator endo-
cytosis in enterocytes (9), as well as for the endocytic uptake of
-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-type
glutamate receptors (AMPARs) in hippocampal neurons (10).
MyosinVI is also involved in the later stages of endocytosis. The
myosin VI no insert (NI) isoform has been implicated in the
transport of uncoated endocytic vesicles through the cortical
actin network to early endosomes (11) and is required for the
sorting of cargo at early endosomes and the delivery of cargo
from early endosomes to endocytic recycling compartments
(12, 13).
It is crucial to understand the specifics of these varied func-
tional roles for myosin VI, as abnormalities in myosin VI func-
tion have been linked to such diseases as prostate and ovarian
cancer (14, 15), hypertrophic cardiomyopathy (16), neurode-
generation (10), and deafness (17–19). Perhaps themost critical
target for such directed studies ofmyosinVI function is thewell
established role formyosin VI in the vesicle transport processes
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of the endocytic uptake pathway, as it is likely that this function
makes a major contribution to the motor disease involvement.
For example, defects inmyosin VI-driven endocytic membrane
transport processes in stereocilia may cause deafness, absence
of myosin VI causes accumulation of cystic fibrosis transmem-
brane conductance regulator in enterocytes leading to secre-
tory diarrhea, and the lack of endocytosis of specific glutamate
receptors in myosin VI-depleted cells may result in neurode-
generation (7, 10, 20). Thus, a thorough understanding of the
roles of myosin VI in endocytosis is critical for identifying
the endocyticmalfunctions thatmay cause specific diseases and
the subsequent development of new targeted treatments to cor-
rect these malfunctions.
Although some of the features of myosin VI involvement in
endocytosis are known (e.g. the binding partners involved), the
specifics of its function on this pathway still require direct
investigation. It has been suggested that the myosin VI LI iso-
form in polarized epithelial cells plays a role in the clustering of
cell surface receptors into a clathrin-coated pit, in the forma-
tion of clathrin-coated vesicles, and in clathrin-coated vesicle
transport away from the plasma membrane (21, 22), but no
studies have so far demonstrated directly whether the myosin
VI LI isoform plays a short or long term role in such tethering/
transport processes or investigated the turnover kinetics of its
association with clathrin-coated structures. On a more funda-
mental level, it is not clear whether myosin VI functions in
endocytosis as a monomer or a dimer, a question of great
importance in the field given the widespread dissent as to
whether myosin VI has a natural tendency toward self-
dimerization (23, 24). In particular, it has not been addressed
whether myosin VI might transfer dynamically between an
inactive, folded, monomeric conformation in the cytosol (com-
parable with that of myosin VII) (25, 26) and an active,
unfolded, dimeric conformation (e.g. when actively bound via
Dab2 to clathrin-coated vesicles) (24, 27, 28).
In this study, we investigate the specifics of the dynamic asso-
ciation of myosin VI with clathrin-coated structures and early
endosomes using the microscopic method of fluorescence
recovery after photobleaching (FRAP). As an initial probe into
the basic kinetics of myosin VI involvement in endocytosis, we
demonstrate the dynamic exchange and characteristic half-life
of themyosin VINI isoform on early endosomes andmyosin VI
LI isoformon clathrin-coated structures.We then demonstrate
that the characteristic half-life of myosin VI is shared by Dab2,
the binding partner known to recruit myosin VI to clathrin-
coated structures. Our FRAP assay is then used to examine the
turnover dynamics of myosin VImutant constructs, a means of
gaining insight into the behavior of myosin VI on the endocytic
pathway. The results indicate that myosin VI is likely to behave
as a functionalmonomer or as a dynamicmonomer/dimer dur-
ing endocytosis, because a novel artificial dimer construct of
myosin VI designed for live cell expression displays strikingly
different turnover dynamics from wild type myosin VI. The
observation that a tail construct of myosin VI turns over at the
same rate as the full-length molecule targets the tail domain as
a critical determinant of turnover dynamics. Taken together,
these results provide insight into the dynamics and monomer/
dimer nature of myosin VI during endocytosis.
EXPERIMENTAL PROCEDURES
Antibodies—The following primary antibodies were used:
rabbit polyclonal antibody to GFP (Invitrogen); mouse mono-
clonal antibody to clathrin (Abcam); mouse monoclonal anti-
body to Rab5 (BD Biosciences).
Cell Culture and Transfection—The HeLa cell line used in
this study was maintained at 37 °C in Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen) supplemented with 10%
fetal calf serum (FCS) (Sigma-Aldrich), 2 mM L-glutamine, and
penicillin/streptomycin (Sigma-Aldrich). Retinal pigment epi-
thelial (RPE) cells were maintained at 37 °C in a 1:1 mixture of
DMEMandHam’sNutrientMixture F-12 (Invitrogen), supple-
mentedwith 10%FCS, 2mML-glutamine, penicillin/streptomy-
cin, and 2% sodium bicarbonate (Invitrogen). Chinese Hamster
Ovary (CHO) cells were maintained at 37 °C in Ham’s Nutrient
Mixture F-12, supplemented with 10% FCS, 2 mM L-glutamine,
and penicillin/streptomycin.
Transfection of the plasmids into tissue culture cells was exe-
cuted according to the instructions provided by the manufac-
turer of the FuGENE transfection reagent (Roche Diagnostics).
Before transfection, cells were grown to 50% confluence on a
6-well tissue culture tray (Greiner Bio-One). Unless otherwise
specified, 2 g of plasmid DNA and 6 l of FuGENE transfec-
tion reagent diluted in 95 l of OptiMEM I (Invitrogen) were
used for each given transfection in 1 well of the 6-well tray.
Immunofluorescence—Cells for use in immunofluorescence
experiments were grown overnight on square coverslips placed
in 6-well trays. Coverslips were then incubated in 0.05% sapo-
nin in phosphate-buffered saline (PBS) for 30 s before fixing
with 4% paraformaldehyde in PBS for 20 min, permeabilized in
0.2% Triton X-100 in PBS for 5 min, quenched with 10 mM
glycine in PBS for 15 min, and blocked in 1% BSA in PBS for 30
min. After blocking, coverslips were incubated for 1 h in pri-
mary antibodies, washed with PBS for three 5-min intervals,
incubated for 1 h in the appropriate secondary antibodies, and
then washed with PBS in five 5-min intervals. The coverslips
were then mounted on glass slides (Agar Scientific) with Pro-
long Gold Antifade Mounting Reagent (Molecular Probes).
Myosin VI Leucine Zipper Construct for in Vivo Expression—
The artificially dimerized form of myosin VI used in many in
vitro studies over the last 10 years consists of a form of porcine
myosinVI truncated in the tail domain after amino acid 992 and
containing a C-terminal GCN4 leucine zipper sequence
(MKQLEDKVEELLSKNYHLENEVARLKKLVGER) (29, 30).
We designed a unique, full-length form of large insert, human
myosin VI with the same GCN4 leucine zipper sequence
(designed to follow a human codon bias) placed as an insert
after the corresponding human amino acid 991 (GenScript).
This version of the artificial dimer is distinguished by its capac-
ity for live cell expression, as it retains the targeting regions in
the myosin VI tail domain.
Plasmids Used for in Vivo Expression—The constructs used
in this work were subcloned into mammalian expression vec-
tors for transfection into HeLa or RPE cells. Full-length wild
typemyosinVI LI, wild typemyosinVI, and the tail construct of
myosin VI LI (excluding the first 838N-terminal amino acids of
the myosin VI protein) were each subcloned into the XhoI/
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SacII sites of a pEGFP-C3 vector (Clontech). Dab2 was sub-
cloned into the EcoRI/SalI sites of a pEGFP-C2 vector (Clon-
tech). The full-length myosin VI LI leucine zipper construct
was subcloned into the BamHI/ApaI sites of a pEGFP-C3 vec-
tor, and the myosin VI leucine zipper tail construct (similarly
excluding the first 838N-terminal amino acids of themyosinVI
protein) was subcloned into the XhoI/SalI sites of a pEGFPC3
vector. pEGFPC3-clathrin was kindly provided by Prof. Marga-
ret Robinson (Cambridge Institute for Medical Research).
Mammalian Two-hybrid Assay—The mammalian two-hy-
brid assay was conducted as described in a previous study from
our laboratory (33). In short, three myosin VI “bait” constructs
((i) myosin VI LI globular tail (wild type AA 1030–1285); (ii)
myosin VI LI globular tail  leucine zipper (AA 991–1317
of myosin VI LI leucine zipper construct described above); (iii)
myosin VI LI globular tail with WWY3WLY mutation (wild
type AA 1030–1285)) were cloned into a pMbait vector coding
for the DNA-binding domain of the GAL4 transcription factor
(Clontech). Dab2 (AA 550–770) was cloned into a pV16 “prey”
vector coding for an activating domain derived from herpes
simplex virus type 1 (Clontech). These bait and prey vectors
were then co-transfected into CHO cells with a reporter plas-
mid coding for constitutively expressedRenilla luciferase (pRL-
CMV; Promega Corp.) and a GAL4-inducible reporter plasmid
coding for firefly luciferase expression (pG5luc; Promega) (0.5
g each). CHOcells were grown for 48 h, lysed in a Passive Lysis
buffer (Promega), and assayed for Renilla and firefly luciferase
with a Dual-Luciferase Reporter Assay system (Promega). As a
negative control, background luciferase activity was measured
in cells transfected with pRL-CMV, pG5luc, Dab2/pV16, and
an empty pM vector. Luciferase activity for each construct was
calculated as the ratio of firefly to Renilla activity for that con-
struct divided by the ratio of firefly to Renilla activity for the
negative control.
FRAP Microscopy Assay—FRAP experiments were carried
out on a Zeiss LSM 510 Incubated Confocal Microscope (Carl
Zeiss, Inc.) with a heated stage and a Plan-Apochromat 63
lens. Images were acquired using LSM 510 acquisition software
(Carl Zeiss, Inc.). Cells were incubated at 37 °C during
acquisition.
During each FRAP experiment, a specific 40  40-pixel
region at the cell base containing fluorescent constructs of
interest was selected for study. Five single-scanned images of
the entire cell containing this region were acquired. The region
was then photobleached with 75 successive scans with a
488-nm argon laser line. Images of the entire cell were again
acquired for the 2.5 min following bleaching. After image
acquisition was complete, the Zeiss LSM510 software was used
to record the fluorescence intensity (arbitrary units) at each
time point of both the bleached region and an unbleached ref-
erence region of the same dimensions and similar fluorescence
level in an adjacent cell.
The FRAP data sets for each construct consisted of between
5 and 11 HeLa or RPE cells transfected with the construct of
interest. Each FRAP study utilized between 4 and 6 individual
sets of this type. Thus, no FRAP results are presented for which
4 data sets of at least 5 cells each were analyzed.
Quantification of Half-life (t1⁄2) Values from FRAP Data—
Analysis of FRAP photobleaching experiments was conducted
by using Microsoft Excel and OriginPro to evaluate intensity
data exported fromZeiss LSM imaging software. To correct the
fluorescence intensities in the 40 40-pixel bleached region for
photobleaching due to image acquisition, the intensities at each
time point were multiplied by the inverse of the fluorescence
intensity of an unbleached, 40 40-pixel reference region with
a similar concentration of fluorescent structures in a nearby
control cell. The resulting, corrected intensity values were used
in the half-life calculations described below.
All FRAP analysis was conducted with the traditional repre-
sentation of a given exchange/turnover process as a pseudo-
first-order reaction. To confirm the validity of such analysis for
our particular system, we quantified the relative levels of a rep-
resentative fluorescent myosin VI construct (myosin VI LI) on
endocytic structures versus in the surrounding cytoplasm. We
found that levels of this representative construct are in signifi-
cant excess in the cytoplasm versus on endocytic structures
(50  30-fold (S.D.) higher concentration in the cytoplasm;
p  6  1010). This significant cytoplasmic surplus indicates
that the rate-limiting factor in a given exchange reaction is the
first-order reaction of construct dissociation from endocytic
structures. As such, FRAP exchange reactions can reasonably
be analyzed as pseudo-first-order reactions for any given cell
and should not be affected by relative construct expression lev-
els. For reference, however, we have provided the overall
expression levels of each construct analyzed (supplemental
Table 1).
The half-life and percentage recovery were calculated for
dynamic proteins in a manner comparable with the methods of
a previous study (31). Prior to calculation, all images were cor-
rected for photobleaching (as described above), normalized to a
starting value of 1, and converted to real-time values (with pre-
bleach as a negative time value, post-bleach as 0 s, and all sub-
sequent images increasing in time from this zero point). The
half-life was determined by fitting a single exponential to a plot
of fluorescence in the experimental region versus real time in
OriginPro. The percentage of fluorescence recovery was calcu-
lated from the asymptote provided by this single exponential fit.
Analysis of Expression Levels—The overall expression level of
each construct was quantified by calculating the average total
fluorescent intensity (arbitrary intensity units) at the base of 15
independent cells expressing the relevant construct (supple-
mental Table 1). Images for this analysis were acquired on a
Zeiss LSMmicroscope with a 63 oil lens. Intensity levels were
analyzed using Volocity Analysis software (PerkinElmer Life
Sciences).
The ratio of cytoplasmic versus clathrin-coated structure-
bound fluorescent constructs was determined using a reference
examination of large insert myosin VI in HeLa cells. For these
studies, a Zeiss LSM 510 microscope with a 63 oil lens was
used to collect Z-stack images of 15 independent HeLa cells
expressing eGFP-tagged myosin VI LI. In accordance with the
Nyquist-Shannon sampling theorem, images were acquired at
0.5-m intervals from the cell base to the top of the cell.
MetaMorph imaging software (Molecular Devices) was then
used to calculate the sum of the fluorescent construct intensity
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on punctate, clathrin-coated structures versus the surrounding
cytoplasm for each slice of each Z-stack. Intensity levels for
these regions were summed for each slice of a given cell to find
the total sum of clathrin-associated versus cytoplasmic myosin
VI LI fluorescence in each cell. The ratios of cytoplasmic to
clathrin-coated structure-bound myosin VI for each cell were
then calculated and averaged to demonstrate the significant
cytoplasmic excess of this representative fluorescent construct.
Image Processing—Individual images were processed in
Adobe Photoshop, and figures were assembled in Adobe
Illustrator.
RESULTS
In this study, we used a FRAP assay to examine the lifetime
and dynamics of myosin VI on endocytic structures. After first
probing the basics of the turnover of myosin VI isoforms on
clathrin-coated structures and early endosomes, we applied our
assay to an investigation of the dynamic behavior of myosin VI
variants in the endocytic pathway.
TheLI andNI Isoforms ofMyosinVITurnOverDynamically on
Endocytic Structures with the Same Characteristic Half-life—We
began our examination of myosin VI during endocytosis by
using FRAP to examine the dynamics of two different myosin
VI isoforms on the specific endocytic structures to which they
are recruited.
The localization of the large insert isoform of myosin VI to
clathrin-coated structures (CCSs) has been well established.
For example, endogenous large insert myosin VI has been
shown to localize to clathrin-coated vesicles in the apical
domain of polarized Caco-2 cells (7). Although the large insert
isoform of myosin VI is not endogenously expressed in HeLa
cells, fluorescently taggedmyosin VI LI-eGFP constructs local-
ize to clathrin-coated structures at the plasma membrane of
HeLa cells in a manner similar to the endogenous LI isoform in
other cell lines (Fig. 1A, a–c) (7). As such, the robust and easy to
handle HeLa cell line has previously been used as a system for
the examination of myosin VI LI on clathrin-coated structures
(32) and was used in this study to examine the dynamic behav-
ior of large insert myosin VI. The recruitment of myosin VI LI
to clathrin-coated pits/vesicles in this system produces charac-
teristic small, round punctae at the plasma membrane that are
easy to identify and select for photobleaching experiments (Fig.
1A, a–c).
The NI isoform of myosin VI is endogenously expressed in
HeLa and RPE cells, and the functions of this isoform in endo-
cytosis have been previously probed by expressing this isoform
in RPE cells and studying its targeting to early endosomes (13,
32). After confirming the localization of eGFP-tagged myosin
VINI to early endosomes labeledwith the characteristicmarker
protein Rab5 (Fig. 1A, d–f), we used the RPE cell line to examine
the dynamic behavior of myosin VI NI. As is evident from the
lower panel of Fig. 1A, the recruitment of myosin VI NI to early
endosomes similarly produces a characteristic phenotype of
round punctae in the cortical actin network beneath the plasma
membrane that are easy to identify and select for photobleach-
ing experiments.
We used a traditional FRAP imaging process to examine the
turnover of myosin VI on clathrin-coated structures or early
endosomes (Fig. 1B). For example, prior to bleaching (pre-
bleach), myosin VI LI-eGFP constructs were localized to punc-
tate clathrin-coated structures near the plasma membrane at
the base of a HeLa cell (Fig. 1Ba). After targeted bleaching of a
selected region of interest (post-bleach), the fluorescence
intensity of the myosin VI LI on the multiple clathrin-coated
structures within this region was extinguished (Fig. 1Bb). Mon-
itoring this experimental region for the 2.5-min period after
bleaching revealed that our FRAP system was sensitive enough
to observe the dynamic replacement of bleached constructs on
clathrin-coated structures in the experimental region with
unbleached, fluorescent constructs from the surrounding area
(Fig. 1Bc).
To analyze these FRAP data, the fluorescence intensities in
specific regions of interest from each cell were corrected for
photobleaching, averaged in sets of 5–9 cells, and plotted versus
time to produce a recovery curve for a given set. The recovery
curves were fit to a single exponential equation to determine
the half-life (t1⁄2) of this turnover process for each protein, which
represents the time required for half of the construct fluores-
cence that will eventually recover to a given region to return to
that region. Average half-lives for each construct were calcu-
lated from 4–5 sets of 5–9 individual cells.
Recovery curveswere plotted for the data sets used to analyze
the dynamic turnover ofmyosinVI LI-eGFP on clathrin-coated
structures in HeLa cells and for myosin VI NI-eGFP on early
endosomes in RPE cells (Fig. 1C). These plots take on the char-
acteristic drop-and-gradual-rise shape of dynamic proteins,
indicating that both isoforms of myosin VI turn over dynami-
cally on endocytic structures. Comparison of the quantified
half-lives of each isoform reveals that myosin VI NI has the
same characteristic half-life on early endosomes in RPE cells
(t1⁄2 16 1 s) as myosin VI LI on clathrin-coated structures in
HeLa cells (t1⁄2 13 2 s) (p 0.3) (Fig. 1D). Fig. 1E provides a
line diagram comparison of these wild type myosin VI full-
length LI and NI constructs with the truncated and mutant
myosin VI constructs utilized in the ensuing subsections of this
study.
Comparison with Other Members of the Endocytic Machinery:
Myosin VI-binding Partner Dab2 Turns Over on Clathrin-coated
Structures at the SameRateasMyosinVILI;ClathrinHasa2-Fold
LongerHalf-lifeThanWildTypeMyosinVI LI—Wenext applied
the robust system of analyzing turnover on clathrin-coated ves-
icles in HeLa cells to the comparative investigation of the turn-
over rates of two related proteins on the endocytic pathway: the
myosin VI-binding partner Dab2 and the coat protein clathrin.
Dab2 binds tomyosin VI and to the coat protein clathrin and
has been shown to actively recruit myosin VI to clathrin-coated
vesicles during endocytosis (32, 33). In fact, forms of myosin VI
containing mutations in theWWY region of the tail domain to
which Dab2 binds no longer associate with clathrin and so do
not display their characteristic punctate, clathrin-coated struc-
ture-associated expression patterns at the cell surface (32).
FRAP of the turnover of Dab2 on clathrin-coated structures in
HeLa cells reveals that Dab2 turns over dynamically with a half-
life of 10 1 s, which is very similar to the half-life ofmyosin VI
LI (t1⁄2 13 2 s) (p 0.2) (Fig. 2, A and C).
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Clathrin proteins actively coat the endocytic vesicles and pits
at the plasma membrane with which myosin VI LI associates,
and their dynamic coating and uncoating behavior has been
well characterized (34). Clathrin ((t1⁄2  28  3 s) has a 2-fold
longer half-life on clathrin-coated structures thanmyosin VI LI
((t1⁄2 13 2 s) (p 0.001) (Fig. 2, B and C).
MyosinVI LIConstructs ArtificiallyDimerizedwith a Leucine
Zipper Turn Over on Clathrin-coated Structures with a 4-Fold
Longer Half-life Than Wild Type Myosin VI LI—We next used
our FRAP system for a systematic investigation of the func-
tional behavior of myosin VI during endocytosis. To probe the
fundamental question of whethermyosinVI operates as amon-
omer or dimer in intracellular trafficking, we examined the
turnover of a full-length, artificially dimerized construct of
myosin VI relative to the wild type form.Wemodeled this arti-
ficial dimer construct on the myosin VI leucine zipper con-
struct used in themajority of the in vitro biochemical studies of
the properties of myosin VI (30, 35, 36). Our construct is
dimerized with the same GCN4 leucine zipper sequence (32
AA) as the original construct, placed after the same amino acid
FIGURE 1. The LI and NI isoforms of myosin VI turn over dynamically on endocytic structures with the same half-life. A, myosin VI LI co-localizes with
clathrin-coated structures in HeLa cells. a–c, sample images at the base of a HeLa cell transfected with eGFP-tagged myosin VI LI (a) and labeled in red for
endogenous clathrin (b) demonstrate co-localizationbetweenmyosinVI LI and the clathrin-coatedpits/vesicles at theplasmamembrane (c). Cellswere labeled
by immunofluorescencewith apolyclonal antibody toeGFPandamonoclonal antibody to clathrin.MyosinVINI co-localizeswithearly endosomes.d–f, sample
images at the base of an RPE cell transfected with eGFP-tagged myosin VI NI (d) and labeled in red for the endogenous early endosome marker Rab5 (e)
demonstrate co-localization between myosin VI NI and early endosomes at the plasmamembrane (f). Scale bar, 2.5 m. B, FRAP methodology. a, pre-bleach:
at the start of imaging, themyosin VI is localized to punctate, clathrin-coated structures at the base of a HeLa cell. b, post-bleach: the fluorescence intensity of
myosin VI proteins within the region of interest (markedwith awhite square) has been depleted by targeted bleaching with a high intensity laser line. c, final:
within the 2.5-min imaging period, the bleached myosin VI proteins in the region of interest dissociate from clathrin-coated structures and are dynamically
replaced by fluorescentmyosin VI proteins from unbleached regions. Scale bar, 50m. C, FRAP ofMVI LI on clathrin-coated structures in HeLa cells andMVI NI
on early endosomes in RPE cells is shown. Each plot represents an average of 1 data set (5 individual cells (myosin VI NI) or 9 individual cells (myosin VI LI)); all
intensity values were corrected for photobleaching due to image acquisition and normalized to a starting value of 1 before plotting. The solid line in each plot
represents a single exponential fit to thedata (R2 0.97 for LI, 0.99 forNI). Representative pre-bleach, post-bleach, and final images are displayed for reference.
Scale bar, 5m. D, half-life values for myosin VI LI on clathrin-coated structures in HeLa cells (t1⁄2 13 2 s) andmyosin VI NI on early endosomes in RPE cells
(t1⁄2 16 1 s) are shown. The difference in values is not significant (unpaired t test, n 5 sets of 5–9 cells for each construct; p 0.3). Error bars represent S.E.
NS, no significance. E, schematic shows domain structure of the eGFP-tagged myosin VI constructs used in this work. The wild type (WT) myosin VI LI and NI
full-length constructs demonstrate that myosin VI consists of a motor domain (AA 1–759 of myosin VI), neck region, and IQ motif (AA 760–838 of myosin VI),
proximal and medial tail domains (AA 839–980 of myosin VI), and a cargo-binding domain (AA 981–1285 of myosin VI). The following portions of this study
utilize a tail construct of myosin VI (expressed from amino acid 839 to remove the motor domain/neck domain/IQ motif) and full-length, and tail forms of a
myosin VI construct artificially dimerized by the inclusion of a leucine zipper region as an insert after amino acid 991 in the cargo-binding domain.
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in the tail region (human amino acid 991 ofmyosinVI) (Fig. 1E).
Rather than truncating the construct after this leucine zipper
like the original version, however, we have included the zipper
as an insert in the full-length protein. This allows us to preserve
the cargo-binding regions in the C-terminal tail domain neces-
sary for association with adaptor proteins and lipids such as
PIP2 required for proper intracellular targeting and recruit-
ment to endocytic structures. Like the eGFP-tagged wild type
myosin VI construct, the leucine zipper construct is expressed
at the C terminus of eGFP.
Because an artificially dimerized form ofmammalianmyosin
VI has never before been viewed in live cells, we conducted an
initial screen to assess its in vivo expression patterns, intracel-
lular targeting, and suitability for our FRAP assay. The leucine
zipper myosin VI LI construct shows a localization very similar
towild typemyosinVI LI and similarly demonstrates noticeable
targeting to punctate, clathrin-coated structures near the
plasmamembrane ofHeLa cells fixed and labeledwith antibod-
ies to clathrin (Fig. 3A). To confirm the resulting implication
that Dab2 binding is not impaired in the leucine zipper con-
struct and that this construct is actively recruited to clathrin-
coated structures via Dab2 binding, we used amammalian two-
hybrid assay to demonstrate that a leucine zipper myosin VI LI
globular tail construct (AA 991–1317) binds to Dab2 in vivo
(AA 550–770) in a manner similar to a wild type myosin VI LI
globular tail construct (AA 1030–1285) (p 0.7, supplemental
Fig. 1). In comparison, in vivoDab2 binding is completely abol-
ished in a myosin VI LI globular tail construct containing a
single point mutation in the Dab2-binding region of the tail
(WWY3WLY, AA 1030–1285) (supplemental Fig. 1).
FRAPwas then used to assess the turnover rate of the leucine
zipper full-length myosin VI LI construct on clathrin-coated
vesicles (Fig. 3B). This construct has a 4-fold longer half-life
(t1⁄2 48 8 s) than wild type myosin VI (t1⁄2 13 2 s) (p
0.002) (Fig. 3C).
Myosin VI LI Tail Construct Turns Over at the Same Rate as
Full-length Myosin VI LI on Clathrin-coated Structures—To
examine the relative importance of the myosin VI tail region in
determining the dynamic interaction with membranes in the
endocytic pathway, we compared the behavior of an eGFP-
tagged tail construct of myosin VI LI on clathrin-coated struc-
tures with full-length myosin VI LI. This tail construct consists
of the C-terminal portion of the protein (proximal and medial
tail regions plus the cargo-binding domain), expressed from
amino acid 839 of the full-length construct to exclude the
motor, neck, and IQ motif present at the N terminus (Fig. 1E).
Most importantly, this tail construct contains the binding
domains for Dab2 and PIP2 required for targeting to clathrin-
coated structures at the plasma membrane.
The tail domain interacts dynamically with clathrin-coated
structures with a half-life of 14  1 s, which is similar to that
found for full-length myosin VI (t1⁄2  13  2 s) (p  0.2),
suggesting that the tail region is the primary determinant of the
interaction time (Fig. 4, A and C).
We also quantified the half-life of a dimeric tail construct
containing a leucine zipper motif after the domain originally
thought to be the coiled-coil-forming region (Fig. 1E). The half-
life of this construct (49 16 s) is similar to that found for the
dimerized full-length construct (48 8 s) (p 0.9), again sug-
FIGURE 2.Comparisonwith othermembers of the endocyticmachinery. A and B, FRAP of Dab2 (A) and clathrin constructs (B) on clathrin-coated structures
in HeLa cells. Each plot represents an average of 1 data set (6 individual cells (Dab2) or 9 individual cells (clathrin) 0. The solid line in each plot represents a single
exponential fit to the data (R2 0.98 (A), 0.99 (B)). Scale bar, 5m. C, half-life values for Dab2 (t1⁄2 10 1 s) and clathrin (t1⁄2 28 3 s), in comparison with
full-lengthmyosin VI LI (t1⁄2 13 2 s). There is no significant difference in the half-life values formyosin VI LI and Dab2 (unpaired t test, n 5 sets of 5–9 cells
for each construct;p0.2). However, clathrinhas a2-fold longerhalf-life thanmyosinVI LI (unpaired t test,n5 sets of 5–10 cells for each construct;p0.001).
Error bars represent S.E. NS, no significance. ***, p 0.001.
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gesting that the tail region is of prime importance in determin-
ing these dynamics (Fig. 4, B and D).
Summary of Half-life and Percentage Recovery Values—For
clarity, the half-life values of all constructs tested are summarized
in Table 1. This table also displays the average percent recovery of
each construct, a value representing the average percentage of ini-
tial fluorescence returning to a given bleached region with time.
The average percent recovery of all constructs analyzed was com-
parable, with an overall average of 78.74  0.02%. This recovery
level falls within the range seen in other FRAP studies of proteins
involved in the endocytic pathway (e.g. clathrin, actin) (37, 38).
DISCUSSION
We used a FRAP-based assay to examine the turnover and
basic dynamics of myosin VI and its binding partner Dab2 on
membrane structures in the endocytic pathway. The LI isoform
of myosin VI has been shown to associate with clathrin-coated
structures and to play a functional role in the early stages of the
endocytic pathway (7, 9), whereas the NI isoform of myosin VI
has been shown to have a functional role in association with
early endosomes (11, 13). No studies, however, have exam-
ined the dynamics of the recruitment and life time of myosin
VI on these endocytic structures or, in fact, on any intracel-
lular structure. As such we use a FRAP microscopy assay in
HeLa and RPE cells to demonstrate that myosin VI turns
over dynamically on endocytic structures with a reproduci-
ble, characteristic half-life. This robust, characteristic half-
life is consistent across multiple endocytic compartments
(clathrin-coated structures versus early endosomes), across
different myosin VI isoforms (no insert versus large insert
isoforms), and across different cell lines (HeLa versus RPE
cells). The same characteristic half-life is shared by the myo-
sin VI-binding partner Dab2 known to recruit myosin VI to
clathrin-coated pits and vesicles, a result that offers insight
into the relative dynamic behavior of myosin proteins and
their binding partners in general.
FIGURE 3.MyosinVI LI constructs artificially dimerizedwith a leucine zipper turn over on clathrin-coated structureswith a 4-fold longer half-life than
wild typemyosin VI LI. A, upper panel, a–c, artificially dimerizedmyosin VI-eGFP (a) co-localizedwith endogenous clathrin (b) in HeLa cells. Cells were labeled
by immunofluorescencewith a polyclonal antibody to eGFP and amonoclonal antibody to clathrin. Lower panel, d–f, comparative depiction of the distribution
ofwild typemyosinVI-eGFP (d)with respect to clathrin-coated structures (e). The similarity in thedistributionpatterns of thewild type andartificially dimerized
forms is clearly visible. Scale bar, 10 m. B, FRAP of myosin VI LI leucine zipper constructs on clathrin-coated structures in HeLa cells. The plot represents an
average of 1 data set (9 individual cells). The solid line represents a single exponential fit to the data (R2 0.99). Scale bar, 5 m. C, leucine zipper myosin VI LI
has a half-life on clathrin-coated structures (t1⁄2 48 8 s) that is 4-fold longer thanwild typemyosin VI LI (t1⁄2 13 2 s) (unpaired t test, n 4–5 sets of 5–9
cells for each construct; p 0.002). Error bars represent S.E. **, p 0.01.
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Our demonstration that the turnover of the myosin VI LI
isoform on clathrin-coated structures is 2-fold faster than the
turnover of the associated clathrin coat protein offers insight
into the basics of myosin VI function during the early stages of
endocytosis. The more rapid exchange of myosin VI demon-
strates that themotor is not likely to play a long term anchoring
role on a given clathrin-coated structure, but instead may be
involved in short term tethering or transport processes. These
functional implications are reinforced when one compares the
half-life of the large insert myosin VI isoform on clathrin-
coated structures (13 2 s) with the overall, average lifetime of
a clathrin-coated vesicle (30–90 s) (39–41): it is clear from
such a comparison that a given myosin VI LI protein remains
only temporarily associated with a given clathrin-coated struc-
ture, rather than tethering a vesicle long term or stably binding
to one vesicle for transport throughout its life cycle. This is in
agreement with the proposed function for the myosin VI LI
isoform, which localizes to the apical domain of the polarized
epithelial cells in which it is expressed and has been suggested
to transport transmembrane receptors from the tip to the base
of a microvillus (21, 42). In this role, myosin VI moves and
clusters plasmamembrane proteins into a clathrin-coated pit, a
function that requires only a transient association with clath-
rin-coated pits/vesicles. It is interesting to compare this short
term functionality and relatively short half-life of myosin VI on
the endocytic pathway with the more stable role and longer
half-life of myosin II in stress fibers (t1⁄290 s, (43)).
Recruitment and Turnover of Myosin VI on CCSs—Our
experiments provide further insight into the regions and
domains of myosin VI that regulate dynamic recruitment and
turnover on CCSs. Our previous work shows that the cargo-
binding tail containing the Dab2-binding site appears to be suf-
ficient to allow targeting ofmyosinVI toCCSs (32). The present
demonstration that the turnover rate of the myosin VI tail on
CCSs is the same as that of the full-lengthmolecule agrees with
these previous data and appears to imply that themotor domain
with its ATPase- and actin-binding activities plays no part in
myosin VI recruitment and turnover on these structures. How-
FIGURE 4. Wild type and artificially dimerized myosin VI LI tail constructs turn over at the same rate as their full-length counterparts on clathrin-
coated structures.A, FRAP recovery curve forwild typemyosin VI LI tail construct. This plot represents an average of 1 data set (8 individual cells). The solid line
represents a single exponential fit to the data (R2 0.99). Scale bar, 5m. B, FRAP of the leucine zippermyosin VI LI tail construct on clathrin-coated structures
in HeLa cells. This plot represents an average of 1 data set (11 individual cells). The solid line represents a single exponential fit to the data (R2 0.99). Scale bar,
5m. C, half-life value for the wild typemyosin VI LI tail construct (t1⁄2 14 1 s), in comparisonwith full-length, wild typemyosin VI LI (t1⁄2 13 2 s). There
is no significant differencebetween these values (p0.6).D, half-life value for the leucine zippermyosinVI LI tail construct (t1⁄24916 s), in comparisonwith
full-length leucine zippermyosinVI LI (t1⁄2488 s). There is no significantdifferencebetween these values (unpaired t test,n4–6 sets of 5–11 cells for each
construct; p 0.9). Error bars represent S.E. NS, no significance.
TABLE 1
Half-life and percentage recovery values
FRAP analysis values are displayed in the order in which they are presented under
“Results.” MVI, myosin VI; LI, large insert; LZ, leucine zipper; EE, early endosome;
CCS, clathrin-coated structure.
Protein
Endocytic
structure
Average
half-life
Average
recovery
s %
Wild type MVI NI full EE 16 1 84.27 0.02
Wild type MVI LI full CCS 13 2 74.96 0.02
Dab2 CCS 10 1 84.53 0.02
Clathrin CCS 28 3 76.71 0.02
LZ MVI LI full CCS 48 8 77.48 0.02
Wild type MVI LI tail CCS 14 1 83.332 0.004
LZ MVI LI tail CCS 49 16 69.90 0.02
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ever, the finding that the turnover rates of the tail and its bind-
ing partner Dab2 are the same offers a possible explanation: the
adaptor protein Dab2 recruits myosin VI via its cargo-binding
tail domain, and the resulting complex binds to CCSs via Dab2;
when Dab2 is released, myosin VI is also released. In this sce-
nario, a tail construct of myosin VI would reasonably share the
sameDab2-based turnover dynamics as the full-length protein.
This suggestion of a binding partner as the determinant ofmyo-
sin VI turnover dynamics provides insight into the general
interaction between myosin proteins and their binding
partners.
Monomer/Dimer Nature ofMyosin VI—Themonomeric ver-
sus dimeric nature of myosin VI has been a fundamental ques-
tion in the field for many years now. The original prediction of
a coiled-coil -helical region due to a repeating sequence in the
myosin VI tail domain was viewed as an indication of the natu-
rally dimeric nature of myosin VI (23). As such, the majority of
the in vitro characterizations of myosin VI to date have been
conducted using a truncated form of this protein artificially
dimerized via the incorporation of a C-terminal leucine zipper
after amino acid 992 in the porcine myosin VI tail domain.
More recently, however, it was demonstrated that endogenous
pools of myosin VI exist almost entirely in monomeric form
when purified for in vitro studies (1% are dimeric) and sug-
gested that the central region of the myosin VI tail may form a
single -helical domain rather than a coiled-coil (24). Further
studies have suggested that perhaps such natively monomeric
myosin VI is selectively dimerized upon binding of cargo or
other binding partners to form a transient, functionally dimeric
state (44–46). Given these conflicting data, it has become
increasingly essential to determinewhethermyosinVI operates
solely as a dimer, operates solely as a monomer, or undergoes a
functional transition between these states in vivo.
We therefore designed an artificially dimerized leucine zip-
per construct based upon the construct used in the majority of
the in vitro studies of myosin VI (30, 35, 36) but possessing the
unique capacity for live cell functional expression due to our
inclusion of the critical targeting region (cargo-binding
domain) in the tail domain. This construct allowed us to con-
duct a critical comparison of the functional behavior of wild
type versus artificially dimerized myosin VI in the endocytic
pathway in vivo. We demonstrate that an artificially dimerized
form of myosin VI has a 4-fold longer half-life than wild type
myosin VI during turnover on clathrin-coated structures. This
suggests that native myosin VI does not function as a stable
dimer on the endocytic pathway, but rather behaves function-
ally as a monomer or in a dynamic equilibrium between mono-
meric and dimeric states (e.g. in the type of binding partner-
mediated monomer/dimer equilibrium suggested by Yu et al.
(45)). This can be understood in terms of a Dab2-based regula-
tion of myosin VI turnover dynamics if one considers that a
given full-length or tail version of artificially dimerized myosin
VI will necessarily bind to two distinct Dab2 proteins (one to
each tail in the dimer). The half-life-defining release of an arti-
ficial dimer from a clathrin-coated structure will thus depend
on the sequential release of these two distinct Dab2 proteins.
The time required for full detachment by a doubly bound
dimeric protein would therefore reasonably be longer than the
time required for full release of a wild type myosin VI bound to
a clathrin-coated structure solely as a monomer (via one Dab2
attachment site), bound in a wild type population including
bound monomeric and dimeric proteins, or bound as a tran-
siently dimeric protein that splits into individual monomers
before dissociation. Thus, our results demonstrate that myosin
VI does not function in the endocytic pathway as a preformed
stable dimer. This important insight into the functional nature
ofmyosinVI distinctly reduces the likelihoodof one of the three
considered options for myosin VI function (solely monomer,
solely dimer, or a monomer/dimer equilibrium (47, 48)), nar-
rowing future examinations of the functional behavior of myo-
sin VI to a distinction between monomer and monomer/dimer
states.
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